Managed Access Programs for SEG101, Crizanlizumab

Available (expanded access)

Conditions studied: Sickle Cell Disease

In brief

The purpose of this registration is to list Managed Access Programs (MAPs) related to SEG101, Crizanlizumab

Key facts

Study ID

NCT03720626

Run by

Novartis Pharmaceuticals

Last updated by the study team

2026-04-14

Who can join

Age: 12 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.